MabThera/Rituxan

A new decade of disruption: meeting the biosimilar challgenge

As the dust settles on the first ten years of disruption, the spotlight is now on the future as more leading MAbs, including Humira (adalimumab), MabThera (rituximab), Avastin (bevacizumab) and Lucentis

Mylan deal with Roche clears path to biosimilar Herceptin launch

Aside from Herceptin, and biosimilars of Roche's Avastin (bevacizumab) and Rituxan/MabThera (rituximab) are also starting to reach the market.

Mundipharma to launch first MabThera biosimilar in EU

The European Medicines Agency has approved MabThera (rituximab) biosimilar Truxima for use in all of the cancer blockbuster's licensed indications, becoming the first copycat of its kind to win regulatory ... Mundipharma. It showed comparable preclinical,

2016: The year when deal-makers took stock?

Canada for biosimilar versions of Rituxan (rituximab) and Herceptin (trastuzumab). .

Celgene bid to push Revlimid beyond myeloma blocked again

The RELEVANCE study looked at combining Revlimid (lenalidomide) with Roche’s Rituxan (rituximab) as a first-line treatment for patients with follicular lymphoma, one of the most common types of ... grade non-Hodgkin’s lymphoma (NHL), comparing the

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]